
Ternary Therapeutics
AI platform for engineering molecular glues to create a new class of medicines.
About
Ternary Therapeutics is a London-based BioTech startup focused on developing a novel platform that combines physics-informed AI with rapid experimental validation to intentionally engineer molecular glues. Molecular glues are a new class of medicines capable of targeting proteins previously considered undruggable. The company's platform aims to move beyond the historical serendipitous discovery of molecular glues, treating drug discovery as an engineering problem.
Show 6 more similar companies
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Pharmaceuticals
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
A global leader in clinical pharmacology and bioanalytical sciences.
Shares Biotechnology, Pharmaceuticals
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to Ternary Therapeutics?
People comparing tools land here. Get listed beside these.
Copy Ternary Therapeutics's SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Key facts
- Website
- ternarytx.co.uk
- Headquarters
- London, United Kingdom
- Founded
- 2024
- Founders
- Oliver Sexton, Andrew Potterton, Cristian Pinto
- Total funding
- $4M (Seed)
- Business model
- B2B
Funding rounds
- $4M16 Mar 2026
Led by Daphni
Tech stack
Detected on ternarytx.co.uk, last scanned 18 Nov 2026. Run your own scan
- Frontend
- Bootstrap
- CDN
- AWS CloudFront
- Hosting
- AWS
- Email provider
- Google Workspace
Benchmarking
See how your site ranks against 16,849 startups
Ternary Therapeutics sits in the 16th percentile for Domain Rating. Check where yours lands, free.
Check your Domain RatingTernary Therapeutics has a Domain Rating of 9, the 16th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursAgent Readiness
Above median
Scan yoursSite Speed
Top 25%
PageSpeedData Trust
Above median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
Ternary Therapeutics scores 46. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when Ternary Therapeutics changes
Used Ternary Therapeutics? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is Ternary Therapeutics growing?
Yes, fast. Our data shows it raised $4.3M in a Seed in March 2026.
Who owns Ternary Therapeutics?
Ternary Therapeutics is privately held, owned by its founders and investors. Investors on record include Daphni. Exact stakes are not public.
Are there companies like Ternary Therapeutics?
Yes. We list 6 companies like Ternary Therapeutics, including Moderna, Degron Therapeutics and Infinimmune.
What does Ternary Therapeutics do?
This approach allows for the predictable design and scaling of these molecules, expanding the range of druggable targets and opening new therapeutic avenues, particularly for inflammatory and neuroinflammatory diseases.
Is Ternary Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Ternary Therapeutics is 71 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Ternary Therapeutics raised?
Ternary Therapeutics has raised a total of $4M in funding. The most recent round on record is Seed.
SEC filings, insider activity, nonprofit links and pay benchmarks for Ternary Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch Ternary Therapeutics and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

